Multiplex cytokines for immune-related adverse events

WO2026117508A1PCT designated stage Publication Date: 2026-06-04BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
BOARD OF RGT THE UNIV OF TEXAS SYST
Filing Date
2025-11-24
Publication Date
2026-06-04

Smart Images

  • Figure US2025056859_04062026_PF_FP_ABST
    Figure US2025056859_04062026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides methods of predicting / diagnosing immunotherapeutic toxicity in a subject using levels of at least one biomarker protein in a biological sample from the subject, wherein the at least one biomarker protein comprises C4orf47, CXCL1, LMNTD2, ERVV-1, PSRC1, SPRED2, KIF22, MRRF, DAAM1, ABO, MAP9, or any combination thereof. Also provided herein are methods of determining therapeutic regimens for patients based on the biomarker levels.
Need to check novelty before this filing date? Find Prior Art